ArticleEMBO molecular medicine2021
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 89 citations in OpenAlex.
- Design, Synthesis, and Antimicrobial Activity of Novel Cyt-ACS medicinal chemistry letters · 2026Article
- Dual inhibition of respiratory complexes inMicrobiology spectrum · 2026Article
- Visualizing the mechanism of quinol oxidation and inhibition of aScience advances · 2026Article
- Inhibitors of cytochromemBio · 2026Article
- Metabolic perturbation reduces antibiotic tolerance inMicrobiology (Reading, England) · 2026Article
- TheProceedings of the National Academy of Sciences of the United States of America · 2026Article
- A bactericidal tuberculosis drug regimen driven by inhibition of the terminal oxidases by pretomanid.EMBO molecular medicine · 2026Article
- A Series of Pyrazolo-Quinazoline Amines Inhibits the CytochromeJournal of medicinal chemistry · 2026Article
- Mycobacterial respiratory chain enzymes and growth are inhibited by decylubiquinone.Communications biology · 2025Article
- Essential redundancies fuel Mycobacterium tuberculosis adaptation to the host.PLoS pathogens · 2025Review
- Cytochrome bd-II oxidase CyxA promotes the pathogenicity ofVirulence · 2025Article
- Remission spectroscopy resolves the mechanism of action of bedaquiline within living mycobacteria.Nature communications · 2025Article
- A bioluminescence-based chemical screen identifies a bactericidal naphthalene scaffold targeting MmpL3 inbioRxiv : the preprint server for biology · 2025Article
- A Telacebec-Shaped Puzzle Piece in the Treatment of Mycobacterial Diseases.American journal of respiratory and critical care medicine · 2025Article
- Scaffold Hopping Strategy toward New 4‑Aminoquinazolines Active Against Extracellular and Intracellular.ACS medicinal chemistry letters · 2025Article
- Article
- Carbon Monoxide and Prokaryotic Energy Metabolism.International journal of molecular sciences · 2025Review
- Contribution of telacebec to novel drug regimens in a murine tuberculosis model.Antimicrobial agents and chemotherapy · 2025Article
- Proton-Translocating NADH-Ubiquinone Oxidoreductase: Interaction with Artificial Electron Acceptors, Inhibitors, and Potential Medicines.International journal of molecular sciences · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 9 institutions in 5 countries.
Bei Shi LeeSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Kiel HardsDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Curtis A EngelhartDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.
Erik J HasenoehrlDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID 0000-0002-1507-741X
Nitin P KaliaLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Jared S MackenzieAfrica Health Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0002-3089-0900
Ekaterina SviriaevaSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Shi Min Sherilyn ChongSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Malathy Sony S ManimekalaiSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Vanessa H KohDepartment of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
John ChanDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Jiayong XuDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Sylvie AlonsoDepartment of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Marvin J MillerDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.
Adrie J C SteynAfrica Health Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Gerhard GrüberSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Dirk SchnappingerDepartment of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.
Michael BerneyDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Gregory M CookDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Garrett C MoraskiDepartment of Chemistry and Biochemistry, Montana State University, Bozeman, MT, USA.
Kevin PetheSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore.ORCID 0000-0003-0916-8873
Nanyang Technological University · SGAlbert Einstein College of Medicine · USCornell University · USNational University of Singapore · SGUniversity of Auckland · NZAfrica Health Research Institute · ZAMontana State University · USUniversity of Alabama at Birmingham · USUniversity of Notre Dame · US
Funding
Design, Syntheses and Studies of Novel Antituberculosis AgentsR37AI054193 · NIAID · UNIVERSITY OF NOTRE DAME · PI MILLER, MARVIN J · 2016 to 2025
$5.2MEradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidasesR01AI139465 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BERNEY, MICHAEL · 2019 to 2023
$3.2MDesign/Syntheses/Studies/Novel Antituberculosis AgentsR01AI054193 · NIAID · UNIVERSITY OF NOTRE DAME · PI MILLER, MARVIN J · 2004 to 2014
$3.2MInterplay between the Mtb electron transport chain and carbon metabolismR01AI137043 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STEYN, ADRIE JC · 2019 to 2023
$2.1MTargeting terminal respiratory oxidation in Mycobacterium tuberculosis: A novel investigation of Cytochrome bd oxidase functionF30AI138483 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HASENOEHRL, ERIK · 2018 to 2018
$50kNIAID NIH HHS F30 AI138483NIAID NIH HHS R01 AI054193NIAID NIH HHS R01 AI137043NIAID NIH HHS R01 AI139465NIAID NIH HHS R37 AI054193
Abstract
The approval of bedaquiline has placed energy metabolism in the limelight as an attractive target space for tuberculosis antibiotic development. While bedaquiline inhibits the mycobacterial F
Indexed as
Mycobacterium tuberculosisTuberculosisAnimalsAnti-Bacterial AgentsAntitubercular AgentsElectron Transport Complex IVMiceOxidoreductasesAnti-Bacterial AgentsAntitubercular AgentsElectron Transport Complex IVOxidoreductasesantibiotic-tolerancecytochrome bcc-aa3cytochrome bd oxidaseoxidative phosphorylationQ203
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.